Jump Financial’s ImmunityBio IBRX Stock Holding History

Jump Financial’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.32M	Buy	302,700 +292,168	+2,774%	+$2M	0.03%	599
2025 Q4	$20.9K	Buy	+10,532	New	+$23.9K	﹤0.01%	1882
2023 Q3	–	Sell	-22,635	Closed	-$62.9K	–	2020
2023 Q2	$62.9K	Buy	+22,635	New	+$64K	﹤0.01%	1712
2023 Q1	–	Sell	-16,900	Closed	-$85.7K	–	1789
2022 Q4	$85.7K	Buy	+16,900	New	+$92.8K	﹤0.01%	1447
2022 Q2	–	Sell	-21,900	Closed	-$123K	–	1797
2022 Q1	$123K	Buy	21,900 +10,940	+100%	+$67.1K	0.01%	1389
2021 Q4	$66K	Sell	10,960 -118,640	-92%	-$891K	﹤0.01%	1279
2021 Q3	$1.26M	Buy	129,600 +13,857	+12%	+$152K	0.09%	245
2021 Q2	$1.65M	Buy	115,743 +91,305	+374%	+$1.51M	0.16%	153
2021 Q1	$580K	Buy	+24,438	New	+$634K	0.05%	364
2020 Q4	–	Sell	-44,500	Closed	-$309K	–	1047
2020 Q3	$309K	Buy	+44,500	New	+$444K	0.06%	485

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jump Financial's IBRX Position: Q1 2026 in Review

Jump Financial increased its ImmunityBio (IBRX) stake by 2,774% in Q1 2026, buying an estimated $2M and bringing the position to 302,700 shares worth $2.32M. The position accounts for 0.03% of the portfolio, ranked #599.

Jump Financial first reported a position in IBRX in Q3 2020 and has held it in 10 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Jump Financial held 302,700 shares of ImmunityBio worth $2.32M as of Q1 2026.
Jump Financial bought 292,168 ImmunityBio shares in Q1 2026, an estimated $2M.
ImmunityBio made up 0.03% of Jump Financial's portfolio in Q1 2026, its #599 holding.
Jump Financial first reported a position in ImmunityBio in Q3 2020 and has held it in 10 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.